Eyebiotech Ltd.
Clinical trials sponsored by Eyebiotech Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New eye drug EYE103 takes on lucentis in major trial for Diabetes-Related vision loss Results expected Sep 2026 (estimated)
- New eye drug EYE103 takes on standard treatment for Diabetes-Related vision loss Results expected Mar 2027 (estimated)
-
New eye injection shows promise for blinding swelling
Disease control CompletedThis early-stage study tests a new drug called EYE201, given as three eye injections over 12 weeks, to see if it is safe and can help reduce swelling in the back of the eye. It includes people with three different eye conditions that cause vision loss: branch retinal vein occlusi…
Phase 1/2 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New antibody injection aims to tackle blinding eye diseases
Disease control CompletedThis study tested a new drug called EYE103, given as an injection into the eye, for people with diabetic macular edema (DME) or wet age-related macular degeneration (NVAMD). The trial had two parts: first, checking safety at increasing doses in about 12 people, then comparing two…
Phase 1/2 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC